Advanced Glycation End Products in Clinical Nephrology

Kidney and Blood Pressure Research

Volumn 27, Issue 1, 2004, Pages 18-28

  Kalousova M ^a   Zima, T ^a   Tesar V ^a   Stipek S ^a   Sulkova S ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Advanced glycation end products; Angiotensin converting enzyme inhibitors; Carbonyl stress; Diabetes mellitus; Hemodialysis; Inflammation; Oxidative stress; Receptor for advanced glycation end products

Indexed keywords

2 ISOPROPYLIDENEHYDRAZONO 4 OXO 5 THIAZOLIDINYLACETANILIDE; 2 ISOPROPYLIDENEHYDRAZONO 4 OXOTHIAZOLIDIN 5 YLACETANILINIDE; ADVANCED GLYCATION END PRODUCT; ALAGEBRIUM; ALPHA TOCOPHEROL; AMINOGUANIDINE; ANGIOTENSIN ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTIOXIDANT; BENFOTIAMINE; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CELL ADHESION MOLECULE; CYTOKINE; DIALYSIS FLUID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN; GLUTATHIONE; GROWTH FACTOR; HYDRALAZINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LOSARTAN; LOW DENSITY LIPOPROTEIN; N PHENACYLTHIAZOLIUM BROMIDE; NIFEDIPINE; PREGNANCY ASSOCIATED PROTEIN; PYRIDOXAMINE; RAMIPRIL; SERUM AMYLOID A; THIAMINE DERIVATIVE; THIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AMYLOIDOSIS; ANEMIA; ATHEROGENESIS; AUTOIMMUNE DISEASE; CARDIOVASCULAR DISEASE; CAROTID ARTERY DISEASE; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; GLOMERULONEPHRITIS; GLOMERULOSCLEROSIS; HEMODIALYSIS; HEMOFILTRATION; HUMAN; INFLAMMATION; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; NERVE DEGENERATION; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PERIPHERAL NEUROPATHY; PERITONEAL DIALYSIS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; ULTRAFILTRATION; UREMIA;

AMYLOIDOSIS; ARTERIOSCLEROSIS; CLINICAL MEDICINE; DIABETES MELLITUS; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; KIDNEY FAILURE; NEPHROLOGY; RECEPTORS, IMMUNOLOGIC; RENAL DIALYSIS; RENAL REPLACEMENT THERAPY; UREMIA;

EID: 0442277569     PISSN: 14204096     EISSN: None     Source Type: Journal    
DOI: 10.1159/000075533     Document Type: Review

References (115)

1. Maillard LC: Action des acides amines sur les sucres; formation des melaniodines par voie méthodique. CR Acad Sci 1912;154:66-68.
2. Bucala R, Cerami A: Advanced glycosylation: Chemistry, biology and implications for diabetes and aging. Adv Pharmacol 1992;23:1-34.
3. Brownlee M: Advanced protein glycosylation in diabetes and aging. Annu Rev Med 1995;46:223-234.
4. Miyata T, Ueda Y, Schinzato T, Yoshiyasu I, Tanaka S, Kurokawa K, Ypersele de Strihou C, Maeda K: Accumulation of albumin-linked and free-form pentosidine in the circulation of uremic patients with end-stage renal failure: Renal implications in the pathophysiology of pentosidine. J Am Soc Nephrol 1996;7:1198-1206.
5. Ritz E, Deppisch R, Nawroth P: Toxicity of uremia - Does it come from AGE? Nephrol Dial Transplant 1994;9:1-2.
6. Munch G, Gerlach M, Sian J, Wong A, Riederer P: Advanced glycation end products in neurodegeneration: More than early markers of oxidative stress? Ann Neurol 1998;44:S85-S88.
7. Miyata T, Ishiguro N, Yasuda Y, Ito T, Nangaku M, Iwata H, Kurokawa K: Increased pentosidine, an advanced glycation end product, in plasma and synovial fluid from patients with rheumatoid arthritis and its relationship with inflammatory markers. Biochem Biophys Res Commun 1998;244:45-49.
8. Thorpe SR, Baynes JW: Role of the Maillard reaction in diabetes mellitus and diseases of aging. Drugs Aging 1996;9:69-77.
9. Dolhofer-Bliesener R, Lechner B, Deppisch R, Ritz E, Gerbitz KD: Immunological determination of advanced glycosylation end-products in human blood and urine. Nephrol Dial Transplant 1995;10:657-664.
10. Ahmed MU, Thorpe SR, Baynes JW: Identification of Nε- carboxymethyllysine as a degradation product of fructoselysine in glycated protein. J Biol Chem 1986;261:4889-4994.
11. Sell DR, Monnier VM: Structure elucidation of a senescence cross-link from human extracellular matrix: Implication of pentoses in the aging process. J Biol Chem 1989;264:21597-21602.
12. Wells Knecht KJ, Brinkhamann E, Wells Knecht MC, Litchfield JE, Ahmed MU, Reddy S, Zyzak DV, Thorpe SR, Baynes JW: New biomarkers of Maillard reaction damage to proteins. Nephrol Dial Transplant 1996;1:S41-S47.
13. Makita Z, Vlassara H, Cerami A, Bucala R: Immunochemical detection of advanced glycosylation end products in vivo. J Biol Chem 1992;267:5133-5138.
14. Miyata T, Kurokawa K, van Ypersele de Strihou C: Relevance of oxidative and carbonyl stress to long-term uremic complications. Kidney Int 2000;58:S120-S125.
15. Miyata T, Maeda K, Kurokawa K, van Ypersele de Strihou C: Oxidation conspires with glycation to generate noxious advanced glycation end products in renal failure. Nephrol Dial Transplant 1997;12:255-258.
16. Koschinski T, He CJ, Mitsuhashi T, Bucala R, Liu C, Buenting C, Heitmann K, Vlassara H: Orally absorbed reactive glycation products (glycotoxins): An environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci USA 1997;94:6474-6479.
17. Cerami C, Founds H, Nicoll I, Mitsuhashi T, Giordano D, Vanpatten S, LeeA, Al Abed Y, Vlassara H, Bucala R, Cerami A: Tobacco smoke is a source of toxic reactive glycation products. Proc Natl Acad Sci USA 1997;94:13915-13920.
18. Miyata T, van Ypersele de Strihou, Kurokawa K, Baynes JW: Alterations in nonenzymatic biochemistry in uremia: Origin and significance of 'carbonyl stress' in long-term uremic complications. Kidney Int 1999;55:389-399.
19. Miyata T, van Ypersele de Strihou C, Imasawa T, Yoshino A, Ueda Y, Hiroyuki O, Kominami K, Onogi H, Inagi R, Nangaku M, Kurokawa K: Glyoxylase I deficiency is associated with an unusual level of advanced glycation end products in a hemodialyzed patient. Kidney Int 2001;60:2351-2359.
20. Vlassara H: Recent progress in advanced glycation end products and diabetic complications. Diabetes 1997;46:S19-S25.
21. Šebeková K, Kupčová V, Schinzel R, Heidland A: Markedly elevated levels of plasma advanced glycation end products in patients with liver cirrhosis - Amelioration by liver transplantation. J Hepatol 2002;36:66-71.
22. Njorge FG, Monnier VM: The chemistry of the Maillard reaction under physiological conditions: A review. Prog Clin Biol Res 1989;304:85-107.
23. Bierhaus A, Hofmann MA, Ziegler R, Nawroth PP: AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept. Cardiovasc Res 1998;37:586-600.
24. King GL, Brownlee M: The cellular and molecular mechanisms of diabetic complications. Endocrinol Metab Clin North Am 1996;25:255-270.
25. Khalifah RG, Baynes JW, Hudson BG: Amadorins: Novel post-Amadori inhibitors of advanced glycation reactions. Biochem Biophys Res Commun 1999;257:251-258.
26. Weiss MF, Erhard P, Kader-Attia FA, Wu YC, Deoreo PB, Araki A, Glomb MA, Monnier VM: Mechanism for the formation of glycoxidation products in end-stage renal disease. Kidney Int 2000;57:2571-2585.
27. ε-(carboxymethyl)lysine, is a product of both lipid peroxidation and glycation reactions. J Biol Chem 1996;271:9982-9986.
28. Baynes JW, Thorpe SR: Role of oxidative stress in diabetic complications. Diabetes 1999;48:1-9.
29. Wieslander A, Linden T, Musí B, Jarkelid L, Speidel R, Beck W, Henle T, Deppisch R: Exogenous uptake of carbonyl stress compounds promoting AGE formation from peritoneal dialysis fluids; in D'Angelo A, Favaro S, Gambaro G (eds): Advanced Glycation End Products in Nephrology. Contrib Nephrol. Basel, Karger, 2001, vol 131, pp 82-89.
30. Jadoul M, Ueda Y, Yasuda Y, Saito A, Robert A, Ishida N, Kurokawa K, van Ypersele de Strihou C, Miyata T: Influence of hemodialysis membrane type on pentosidine plasma level, a marker of carbonyl stress. Kidney Int 1999;55:2487-2492.
31. Thornalley PJ: Advanced glycation and development of diabetic complications: Unifying the involvement of glucose, methylglyoxal and oxidative stress. Endocrinol Metab 1996;3:149-166.
32. Faist V, Ebersdobler HF: Metabolic transit and in vivo effects of melanoidins and precursor compounds deriving from the Maillard reaction. Ann Nutr Metab 2001;45:1-12.
33. Alaiz M, Hidalgo FJ, Zamora R: Comparative antioxidant activity of Maillard-and oxidized lipid-damaged bovine serum albumin. J Agric Food Chem 1997;45:3250-3254.
34. Vlassara H, Cai W, Cranall J, Goldberg T, Oberstein R, Dardaine V, Peppa M, Rayfield EJ: Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proc Natl Acad Sci USA 2002;99:15596-15601.
35. Uribarri J, Peppa M, Cai W, Goldberg T, Lu M, He C, Vlassara H: Restriction of dietary glycotoxins reduces excessive advanced glycation end products in renal failure patients. J Am Soc Nephrol 2003;14:728-731.
36. Schwedler S, Metzger T, Schinzel R, Wanner C: Advanced glycation end products and mortality in hemodialysis patients. Kidney Int 2002;62:301-310.
37. Wu JT: Advanced glycosylation end products: A new disease marker for diabetes and aging. J Clin Lab Anal 1993;7:252-255.
38. Makita Z, Bucala R, Rayfield EJ, Firedman EA, Kaufman AM, Korbet SM, Barth RH, Winston JW, Fuh H, Manogue KR, Cerami A, Vlassara H: Reactive glycosylation end products in diabetic uraemia and treatment of renal failure. Lancet 1994;343:1519-1522.
39. Miyata T, Ueda Y, Horie K, Nankagu M, Tanaka S, van Ypersele de Strihou C, Kurokawa K: Renal catabolism of advanced glycation end products: The fate of pentosidine. Kidney Int 1998;53:416-422.
40. Amore A, Cirina P, Mitola S, Peruzzi L, Gianoglio B, Rabbone I, Sacchetti C, Cerutti F, Grillo C, Coppo R: Nonenzymatically glycated albumin (Amadori adducts) enhances nitric oxide synthase activity and gene expression in endothelial cells. Kidney Int 1997;51:27-35.
41. Raj DSC, Choudhury D, Welboume TC, Levi M: Advanced glycation end products: A nephrologist's perspective. Am J Kidney Dis 2000;35:365-380.
42. Makita Z, Vlassara H, Rayfield E, Cartwright K, Friedman E, Rodby R, Cerami A, Bucala R: Hemoglobin-AGE: Circulating marker of advanced glycosylation. Science 1992;258:651-653.
43. Thornalley PJ: Cell activation by glycated proteins. AGE receptors, receptor recognition factors and functional classification of AGEs. Cell Mol Biol 1998;44:1013-1023.
44. Bierhaus A, Ritz E, Nawroth PP: Expression of receptor for advanced glycation end-products in occlusive vascular and renal disease. Nephrol Dial Transplant 1996;11(suppl):87-90.
45. Chappey O, Dosquet C, Wautier M-P, Wautier J-L: Advanced glycation end products, oxidant stress and vascular lesions. Eur J Clin Invest 1997;27:97-108.
46. Schmidt AM, Hori O, Cao R, Yan SD, Brett J, Wautier JL, Ogawa S, Kuwabara K, Matsumoto M, Stern D: RAGE: A novel cellular receptor for advanced glycation end products. Diabetes 1996;45:S77-S80.
47. Yan SD, Stern D, Schmidt AM: What's the RAGE? The receptor for advanced glycation end products (RAGE) and the dark side of glucose. Eur J Clin Invest 1997;27:179-181.
48. Abel M, Ritthaler U, Zhang Y, Deng Y, Schmidt AM, Greten J, Sernau T, Wahl P, Andrassy K, Ritz E: Expression of receptors for advanced glycosylated end-products in renal disease. Nephrol Dial Transplant 1995;10:1662-1667.
49. Heidland A, Sebekova K, Schinzel R: Advanced glycation end products and the progressive course of renal disease. Am J Kidney Dis 2001;38(suppl):S100- S106.
50. Yan SD, Schmidt AM, Anderson GM, Zhang J, Brett J, Zou YS, Pinky D, Stern D: Enhanced cellular oxidant stress by the interaction of advanced glycation and products with their receptors/binding proteins. J Biol Chem 1994;269:9889-9897.
51. Kislinger T, Fu C, Huber B, Qu W, Taguchi A, Yan SD, Hofmann M, Yan SF, Pischensrieder M, Stern D, Schmidt AM: Nε-(carboxymethyl) lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem 1999;274:31740-31749.
52. Bierhaus A: Physiological function of RAGE (abstract). AGEs Symp, Jena, 2003, p 6.
53. Li J, Schmidt AM: Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end products. J Biol Chem 1997;272:16498-16506.
54. Kalousová M, Zima T, Tesař V, Lachmanová J: Advanced glycation end products and advanced oxidation protein products in hemodialyzed patients. Blood Purif 2002;20:531-536.
55. Degenhardt TP, Grass L, Reddy S, Thorpe SR, Diamandis EP, Baynes JW: Technical note. The serum concentration of the advanced glycation end-product N epsilon-(carboxymethyl) lysine is increased in uremia. Kidney Int 1997;52:1064-1067.
56. Schinzel R, Munch G, Heidland A, Sebekova K: Advanced glycation end products in endstage renal disease and their removal. Nephron 2001;87:295-303.
57. Kaunachi M, Nishioka H, Dohi K: Serum levels of advanced glycosylation end products in diabetic nephropathy. Nephron 2001;89:228-230.
58. Witko-Sarsat V, Friedlander M, Capeillere-Blandin C, Nguyen-Khoa T, Nguyen AT, Zingraff J, Jungers P, Deschamps-Latscha B: Advanced oxidation protein products as a novel marker of oxidative stress in uraemia. Kidney Int 1996;49:1304-1313.
59. Loughrey CM, Young IS, Lightbody JH, McMaster D, McNamee PT, Trimble ER: Oxidative stress in haemodialysis. Q J Med 1994;87:679-683.
60. Friedlander MA, Wu YC, Schulak JA, Monnier VM, Hricik DE: Influence of dialysis modality on plasma and tissue concentration of pentosidine in patients with end-stage renal disease. Am J Kidney Dis 1995;25:445-451.
61. Henle T, Deppisch R, Beck W, Hergesell O, Hansch GM, Ritz E: Advanced glycated end-products (AGE) during haemodialysis treatment: Discrepant results with different methodologies reflecting the heterogenity of AGE compounds. Nephrol Dial Transplant 1999;14:1968-1975.
62. Zeier M, Deppisch R, Haug U, Schwenger V, Henle T, Bahner U, Wanner C, Schneider H, Ritz E: Resorption of AGE-promoting glucose degradation products (GDP) from peritoneal dialysis (PD) fluids leads to increased levels of AGE in plasma. J Am Soc Nephrol 2000;11:223A.
63. Salahudeen AK, Kanji V, Reckelhoff JF, Schmidt AM: Pathogenesis of diabetic nephropathy: A radical approach. Nephrol Dial Transplant 1997;12:664-668.
64. Munch G, Kies R, Wessel A, Riederer P, Bahner U, Heidland A, Niwa T, Lemke HD, Schinzel R: Determination of advanced glycation and products in serum by fluorescence spectroscopy and competitive ELISA. Eur J Clin Chem Clin Biochem 1997;35:669-677.
65. Papanastasiou P, Grass L, Rodela H, Patrikarea A, Oreopoulos D, Diamandis EP: Immunological quantification of advanced glycosylation end-products in the serum of patients on hemodialysis or CAPD. Kidney Int 1994;46:216-222.
66. Vlassara H: Serum advanced glycosylation end products: A new class of uremic toxins? Blood Purif 1994;12:54-59.
67. Kalousová M, Zima T, Tesař V, Sulková S, Škrha J, Deppisch R, Beck W: Glycoxidation in hemodialyzed patients with diabetes mellitus; in Timio M, Wizemann V, Venanzi S (eds): Cardionephrology. Cosenza, Editoriale Bios, 2002, vol 7, pp 297-300.
68. Kalousová M, Škrha J, Zima T: Advanced glycation end products and advanced oxidation protein products in patients with diabetes mellitus. Physiol Res 2002;51:597-604.
69. Stein G, Franke S, Mahiout A, Schneider S, Sperschneider H, Borst S, Vienken J: Influence of dialysis modalities on serum AGE levels in end-stage renal disease patients. Nephrol Dial Transplant 2001;16:999-1008.
70. Miyata T, Ueda Y, Saitro A, Kurokawa K: Carbonyl stress and dialysis-related amyloidosis. Nephrol Dial Transplant 2000;15(suppl):25-28.
71. Wada T, Miyata T, Kurokawa K: Implication of carbonyl stress in long term uraemic complications. Nephrol Dial Transplant 1999;14(suppl):79-81.
72. Schwedler S, Schinzel R, Vaith P, Wanner C: Inflammation and advanced glycation end products in uremia: Simple coexistence, potentiation or causal relationship? Kidney Int 2001;59:S32-S36.
73. Deppisch RM, Beck W, Goehl H, Ritz E: Complement components as uremic toxins and their potential role as mediators of microinflammation. Kidney Int 2001;59:S271-S277.
74. Acosta J, Hettinga J, Fluckiger R, Krumrei N, Goldfine A, Angarita L, Halperin J: Molecular basis for a link between complement and the vascular complications of diabetes. Proc Natl Acad Sci USA 2000;97:5450-5455.
75. Friedlander MA, Witko-Sarsat V, Nguyen AT, Wu YC, Labrunte M, Verger C, Jungers P, Descamps-Latscha B: The advanced glycation end product pentosidine and monocyte activation. Clin Nephrol 1996;45:379-382.
76. Šebeková K, Podracka L, Heidland A, Schinzel R: Enhanced plasma levels of advanced glycation end products (AGE) and pro-inflammatory cytokines in children/adolescents with chronic renal insufficiency and after renal replacement therapy by dialysis and transplantation - Are they inter-related? Clin Nephrol 2001;56:S21-S26.
77. Kalousová M, Zima T, Tesař V, Sulková S, Fialová L: Relationship between advanced glycoxidation end products, inflammatory markers/acute phase reactants and some autoantibodies in chronic hemodialysis patients. Kidney Int Suppl 2003;84:62-64.
78. Kalousová M, Sulková S, Fialová L, Soukupová J, Malbohan IM, Spacek P, Braun M, Mikulíková L, Fořtová M, Hořejší M, Tesař V, Zima T: Glycoxidation and inflammation in chronic hemodialysis patients. Nephrol Dial Transplant 2003, in press.
79. Bayes-Genis A, Conover CA, Overgaard MT, Bailey KR, Christiansen M, Holmes DR Jr, Virmani R, Oxvig C, Schwartz RS: Pregnancy-associated plasma protein A as a marker of acute coronary syndromes. N Engl J Med 2001;345:1022-1029.
80. Menzel E J, Sobal G, Staudinger A: The role of oxidative stress in the long-term glycation of LDL. Biofactors 1997;6:111-124.
81. Motomiya Y, Oyama N, Iwamoto H, Uchimura T, Maruyama I: N-Epsilon-(carboxymethyl) lysine in blood from maintenance hemodialysis patients may contribute to dialysis-related amyloidosis. Kidney Int 1998;54:1357-1366.
82. Stein G, Busch M, Muller A, Wendt T, Franke C, Niwa T, Franke S: Are advanced glycation end products cardiovascular risk factors in patients with CRF? Am J Kidney Dis 2003;41(suppl 2):S52-S56.
83. Hricik DE, Wu YC, Schulak A, Friedlander MA: Disparate changes in plasma and tissue levels after kidney and kidney-pancreas transplantation. Clin Transplant 1996;10:568-573.
84. Miyata T, Ueda Y, Yoshida A, Sugiyama S, Iida Y, Jadoul M, Maeda K, Kurokawa K, van Ypersele de Strihou C: Clearance of pentosidine, an advanced glycation end product, by different modalities of renal replacement therapy. Kidney Int 1997;51:880-887.
85. Šebeková K, Podracká L, Blazicek P, Syrova D, Heidland A, Schinzel R: Plasma levels of advanced glycation end products in children with renal disease. Pediatr Nephrol 2001;16:1105-1112.
86. Franke S, Muller A, Sommer M, Busch M, Kientsch-Engel R, Stein G: Serum levels of total homocysteine, homocysteine metabolites and of advanced glycation end products (AGEs) in patients after renal transplantation. Clin Nephrol 2003;59:88-97.
87. Heidland A, Frangiosa A, De Santo L, Cirillo M, Rossi, Cotrufo M, Klassen A, Schinzel R, Sebekova K, De Santo N: AGEs in human heart disease: Mild decrease in congestive heart failure and enhanced levels after heart transplantation in the presence of a reduced GFR. Nephrol Dial Transplant 2002;S1:330.
88. Fagugli RM, Vanholder R, De Smet R, Selvi A, Antolini F, Lameire N, Floridi A, Buoncristiani U: Advanced glycation end products: Specific fluorescence changes of pentosidine-like compounds during short daily hemodialysis. Int J Artif Organs 2001;24:256-262.
89. Inagi R, Miyata T: Oxidative protein damage with carbohydrates and lipids in uremia. Carbonyl stress. Blood Purif 1999;17:95-98.
90. Gerdemann A, Wagner Z, Solf A, Bahner U, Heidland A, Vienken J, Schinzel R: Plasma levels of advanced glycation end products during haemodialysis, haemodiafiltration and haemofiltration: Potential importance of dialysate quality. Nephrol Dial Tranplant 2002;17:1045-1049.
91. Tessitore N, Lapolla A, Arico CN, Gammaro L, Bernich P, Fedel D: Hemodialysis techniques and advanced glycation end products; in D'Angelo A, Favaro S, Gambaro G (eds): Advanced Glycation End Products in Nephrology. Contrib Nephrol. Basel, Karger, 2001, vol 131, pp 33-39.
92. Krieter DH, Lemke HD, Gerdermann A, Schinzel R, Heidland A, Baumeister U: Effect of LDL apheresis on the removal of advanced glycation end products (AGE) (abstract). 37th ERA-EDTA Congress. Nice, 2000.
93. Friedlander MA, Wu YC, Elgawish A, Monnier VM: Early and advanced glycosylation end products. Kinetics of formation and clearance in peritoneal membrane. J Clin Invest 1996;97:728-735.
94. Ho-dac-Pannekeet MM, Weiss MF, deWaart DR, Erhard P, Hiralall JK, Krediet RT: Analysis of nonenzymatic glycosylation in vivo: Impact of different dialysis solutions. Perit Dial Int 1999;19(suppl):S68-S74.
95. Lamb E, Cattel WR, Dawnay A: Glycated albumin in serum and dialysate of patients on continuous ambulatory peritoneal dialysis. Clin Sci (Lond) 1993;84:619-626.
96. Ateshkadi A, Johnson CA, Founds HW, Zimmerman SW: Serum advanced glycosylation end products in patients on hemodialysis and CAPD. Perit Dial Int 1995;15:129-133.
97. Yamada K, Miyhara Y, Hamaguchi K, Nakayama M, Nakano H, Nozaki O, Miura Y, Suzuki S, Tuchida H, Mimura N: Immunohistochemical study of human advanced glycosylation end-products (AGE) in chronic renal failure. Clin Nephrol 1994;42:354-361.
98. Nakayama M, Kawaguchi Y, Yamada K, Hasegawa T, Takozoe K, Katoh N, Hayakawa H, Osaka N, Yamamoto H, Ogawa A, Kubo H, Shigematsu T, Sakai O, Horiuchi S: Immunohistochemical detection of advanced glycosylation end-products in the peritoneum and its possible pathophysiological role in CAPD. Kidney Int 1997;51:182-186.
99. Dawnay AB, Millar DJ: Glycation and advanced glycation end product formation with icodextrin and dextrose. Perit Dial Int 1997;17:52-58.
100. Linden T, Forsback G, Deppisch R, Henle T, Wieslander A: 3-Deoxyglucosone, a promoter of advanced glycation end products in fluids for peritoneal dialysis. Perit Dial Int 1998;18:209-213.
101. Zeier M, Schwenger V, Deppisch R, Haug U, Weigel K, Bahner U, Wanner C, Schneider H, Henle T, Ritz E: Glucose degradation products in PD fluids: Do they disappear from the peritoneal cavity and enter the systemic circulation? Kidney Int 2003;63:298-305.
102. Tauer A, Zhang X, Schaub TP, Zimmek T, Niwa T, Passlick-Deetjen J, Pitschensrieder M: Formation of advanced glycation end products during CAPD. Am J Kidney Dis 2003;41(suppl 1):S57-S60.
103. Ueda Y, Miyata T, Goffin E, Yoshino AQ, Inagi R, Ishibashi Y, Izuhara Y, Saito A, Kurokawa K, van Ypersele de Strihou C: Effect of dwell time on carbonyl stress using icodextrin and amino acid peritoneal dialysis fluids. Kidney Int 2000;58:2518-2524.
104. Lee WK, Akyol M, Shaw S, Dominiczak MH, Briggs JD: Kidney transplantation decreases the tissue level of advanced glycosylation end-products. Nephrol Dial Transplant 1995;10:103-107.
105. Singh R, Barden A, Mori T, Beilin L: Advanced glycation end-products: A review. Diabetologia 2001;44:129-146.
106. Miyata T, Kurokawa K, van Ypersele de Strihou C: Advanced glycation and lipooxidation end products: Role of reactive carbonyl compounds generated during carbohydrate and lipid metabolism. J Am Soc Nephrol 2000;11:1744-1752.
107. Alderson NL, Chachich ME, Youssef NN, Beattie RJ, Nachtigal M, Thorpe SR, Baynes JW: The AGE inhibitor pyridoxamine inhibits lipemia and development of renal and vascular disease in Zucker obese rats. Kidney Int 2003;63:2123-2133.
108. Netzel M, Geyer J, Strassl G, Bitsch R, Stracke H, Hammes HP, Werkmann D, Mavrakis K, Federlin KF, Bitsch I: Physiological effects of different thiamine derivatives in diabetic rats (abstract). AGEs Symp, Jena, 2003, p 32.
109. Miyata T, van Ypersele de Strihou C, Ueda Y, Ichimori K, Inagi R, Onogi H, Ishikawa N, Nangaku M, Kurokawa K: Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: Biochemical mechanisms. J Am Soc Nephrol 2002;13:2478-2487.
110. Forbes JM, Cooper ME, Thallas V, Burns WC, Thomas MC, Brammar GC, Lee F, Grant SL, Burrel LA, Jerums G, Osicka TM: Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy. Diabetes 2002;51:3274-3282.
111. Šebeková K, Schinzel R, Munch G, Krivosikova Z, Dzurik R, Heidland A: Advanced glycation end-product levels in subtotally nephrectomized rats: Beneficial effects of angiotensin II receptor 1 antagonist losartan. Mineral Electrolyte Metab 1999;25:380-383.
112. Šebeková K, Gazdíková K, Blazícek P, Schinzel R, Heidland A, Dzúrik R: ACEI ramipril ameliorated circulating AGEs and oxidative stress in patients with non-diabetic kidney disease. Nephrol Dial Transplant 2002;S1:100.
113. Nangaku M, Miyata T, Sada T, Makoto M, Inagi R, Ueda Y, Ishikawa N, Yuzawa H, Koike H, van Ypersele de Strihou C, Kurokawa K: Anti-hypertensive agents inhibit in vivo the formation of advanced glycation end products and improve renal damage in a type 2 diabetic nephropathy rat model. J Am Soc Nephrol 2003;14:1212-1222.
114. Wolffenbuttel BH, Boulanger CM, Crijns FR, Huijberts MS, Poitevin P, Swennen GN, Vasan S, Egan JJ, Ulrich P, Cerami A, Lévy BI: Breakers of advanced glycation end products restore large artery properties in experimental diabetes. Proc Natl Acad Sci USA 1998;95:4630-4634.
115. Hori O, Yan SD, Ogawa S, Kuwabara K, Matsumoto M, Stern D, Schmidt AM: The receptor for advanced glycation end-products has a central role in mediating the effects of advanced glycation end-products on the development of vascular disease in diabetes mellitus. Nephrol Dial Transplant 1996;1:S13-S16.